Generex (GNBT):
Generex said this morning that they had now achieved 75% of the required number of per-protocol completers in its Phase III trial of Oral-lyn. The company noted that early results may suggest that the use of Oral-lyn will support a non-inferiority claim relative to standard of care injectable insulin. The company reiterated that patients taking Oral-lyn on average showed no weight gain and an actual decrease in Body Mass Index (BMI). » Read more: Daily Pharma Watch
ArQule ASCO Data Analysis
This post will be brief, I have to say I am a little disappointed in ArQule at this moment. I’m not necessarily disappointed in the data that they reported at ASCO, it’s still pretty good for NSCLC. I am just disappointed at the fact that there is not any real NEW data being reported. Add in the fact that the company embargoed the abstract until June 5, 2010 which added hype that the company may be reporting OS and ORR data at this years ASCO, but that didn’t happen. » Read more: ArQule Inc. (ARQL) ASCO Data Analysis
ArQule Inc. (ARQL): ARQ-197
Today I’m going to cover ARQ-197. Arqule will be reporting updated data at this year’s ASCO on June 5, 2010 in an oral presentation. This presentation should shine some more light on their lead product ARQ-197 in Non Small Cell Lung Cancer in an Abstract titled: #LBA7502: Results from ARQ 197-209: A global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). » Read more: ArQule Inc (ARQL): ARQ-197
Three ASCO Stocks Reporting new Data at the ASCO Conference
Before i get started I would like investors to know that Delcath and ArQule will be making their non-public data, public at 12:00 Pm on June 5, 2010 at the ASCO Abstract website.
Today, I am going to lay out three stocks that will be presenting updated data that isn’t included in the already released Abstracts at ASCO this year. The data could be a catalyst for share prices if the market reacts favorably. » Read more: Three ASCO Stocks Reporting New Data at the ASCO Conference: Delcath Systems (DCTH), ArQule (ARQL), Provectus (PVCT)
ArQule Inc. (ARQL): ARQ-197
Today I’m going to cover ARQ-197. Arqule will be reporting updated data at this year’s ASCO which should shine some more light on their lead product ARQ-197 in Non Small Cell Lung Cancer in an Abstract titled: #LBA7502: Results from ARQ 197-209: A global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). » Read more: ArQule Inc. (ARQL): ARQ-197 ASCO Full Analysis
© 2010 GekkoWire · Proudly powered by WordPress & Green Park 2 by Cordobo.
Valid XHTML 1.0 Transitional | Valid CSS 3
Twitter